We develop innovative medicines that greatly improve health outcomes for patients with an unremitting focus on quality and affordability. We work with all the top 10 generic pharmaceutical companies in the world. We sell our APIs in 56 countries. Our major focus areas include anti-retroviral, Hepatitis C and Oncology drugs.
Continuous innovation is the lifeblood of our business. Therefore, we undertake dedicated R&D in areas that have significant growth potential. We filed 257 patents in which we own 116 patents. We have commercialised 60+ products since inception across four distinct business units: Generics API, Generics FDF, Ingredients and Synthesis.
As a company, we conduct our business with utmost transparency and integrity. This helps us attract the best talent and win the trust of our stakeholders. Given that we operate in a highly regulated sector, we adopt a high-watermark approach to compliance to ensure that we exceed the requirements of all applicable international standards.
We are making great progress on our strategic goals. See our latest annual report.
We are a science-led company at our core. We push back the frontiers of science to serve the needs of humanity. Our state-of-the-art research labs enable us to produce new cures to some of the most challenging diseases. With our manufacturing facilities, we cracked the code of creating high-quality and affordable medicines. Our facilities have been certified and approved by WHO, USFDA, NIP Hungary, PMDA, KFDA and BfArM. Our strong R&D and API manufacturing capabilities are enabling us to grow rapidly. We are also one of the most-admired companies to work for in the pharmaceutical sector.
State-of-the-art R & D labs in India and the US
APIs manufactured at 8 manufacturing facilities
Million in annual revenues in FY20
Research scientists out of a total workforce of over 3000
Customers across 56 countries
Patents filed and 116 patents granted
Million liters of reactor capacity
Manufacturing Facilities
Laurus Generics GmbH 
Laurus Synthesis 
